AusperBio Completed RMB 100 million in Pre-A+ financing by InnoPinnacle Fund

Nov, 2023. AusperBio（Ausper Biopharma Co.，Ltd. and AusperBio Therapeutics，Inc.）Completed RMB 100 million in Pre-A+ financing by led by InnoPinnacle Fund.

According to the public information, this round of financing will help accelerate the development of global clinical trials of AHB-137 under AusperBio and other innovative targeted delivery Med-Oligo™ small nucleic acid drugs. In October 2022, AusperBio completed a Pre-A round of financing totaling approximately US$16 million by InnoPinnacle Fund. The company’s angel investors continue to be optimistic and will invest additional money in this round.

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to the development of innovative therapeutics for curing chronic hepatitis B. The company has developed a proprietary Med-Oligo™ ASO technology platform, substantially enhancing the potency of targeted therapies, not only for liver diseases, but also with the potential for expansion beyond the liver. AusperBio’s strategy is to combine its leading oligonucleotide therapies with other medications including therapeutic antibodies and mRNA vaccines to address a broad range of unmet medical needs.^[2]https://www.prnewswire.com/news-releases/ausperbio-announces-fda-clearance-of-ind-application-of-ahb-137-in-chronic-hepatitis-b-treatment-301909966.html

Currently, AHB-137 is undergoing clinical trials simultaneously in many countries and regions such as New Zealand, China, and the United States. Through global layout, it is accelerating the goal of functional cure of hepatitis B.